Tn the past, alcoholic liver disease was attributed exclusively to dietary
deficiencies, but experimental and judicious clinical studies have now esta
blished alcohol's hepatotoxicity. Despite an adequate diet, it can contribu
te to the entire spectrum of liver diseases, mainly by generating oxidative
stress through its microsomal metabolism via cytochrome P4502E1 (CYP2E1).
It also interferes with nutrient activation, resulting in changes in nutrit
ional requirements. This is exemplified by methionine, one of the essential
amino acids for humans, which needs to be activated to S-adenosylmethionin
e (SAMe), a process impaired by liver disease. Thus, SAMe rather than methi
onine is the compound that must be supplemented in the presence of signific
ant liver disease. In baboons, SAMe attenuated mitochondrial lesions and re
plenished glutathione; it also significantly reduced mortality in patients
with Child A or B cirrhosis. Similarly, decreased phosphatidylethanolamine
methyltransferase activity is associated with alcoholic liver disease, resu
lting in phosphatidylcholine depletion and serious consequences for the int
egrity of membranes. This can be offset by polyenylphosphatidylcholine (PPC
), a mixture of polyunsaturated phosphatidylcholines comprising dilinoleoyl
phosphatidylcholine (DLPC), which has high bioavailability. PPC (and DLPC)
opposes major toxic effects of alcohol, with down-regulation of CYP2E1 and
reduction of oxidative stress, deactivation of hepatic stellate cells, and
increased collagenase activity, which in baboons, results in prevention of
ethanol-induced septal fibrosis and cirrhosis. Corresponding clinical trial
s are ongoing.